La chaîne d'options affiche les données clés des options sur actions de Aquestive Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Aquestive Therapeutics..

Aquestive Therapeutics (NASDAQ:AQST) Stock, Chaîne d'Options

AQUESTIVE THERAPEUTICS INC

Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics Inc

News

American Shared Hospital Services Q4 Revenue Rises 59.2% YoY To $9.069M, Exits Quarter With Cash And Equivalents Worth $11.275M

Needham analyst Scott Berg reiterates Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $52 price target.

Price Target

Reiteration

Analyst Ratings

FIVN

Needham Reiterates Buy on Five9, Maintains $52 Price Target

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $58 price target.

Rosenblatt Maintains Buy on Five9, Maintains $58 Price Target

Top billionaires Elon Musk, Mark Zuckerberg, and Jensen Huang lost nearly $34 billion after the bloodbath on Wall Street on Thursday. Here&#8217;s how much the &#8216;Magnificent 7&#8217; billionaires lost in total.
What Happened: Wall Street witnessed its most brutal trading day in years, with all major U.S. stock indexes experiencing their largest single-day drops on Thursday since the COVID-19 pandemic.
The richest business leaders lost billions of dollars as the stock market declined. Notably, Meta Platforms Inc.&#8216;s founder, chairman, and CEO, Zuckerberg, lost $17.9 billion in a single day, according to Forbes data.
Amazon.com Inc. founder Jeff Bezos saw his net worth plummet by a staggering $16 billion, while Tesla Inc. co-founder and CEO Musk lost $8.7 billion amid the market selloff.
On the other hand, chipmaker Nvidia Corp.&#8216;s founder and CEO, Huang, saw a $7.4 billion change in his net worth, whereas Microsoft Corp. co-founder Bill Gates&#8216; wealth tumbled by $774 million on Thursday.
Alphabet Inc. co-founders Larry Page and Sergey Brin lost $4.9 billion and $4.6 billion, respectively, while the company&#8217;s CEO, Sundar Pichai, saw his net worth decline by $18 million.
Apple Inc. CEO Tim Cook witnessed a loss of $68 million.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>Thursday&#8217;s Performance</td>
<td>Business Leaders</td>
<td>Change In Wealth (In Billion Dollars)</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>-26.40%</td>
<td>-7.81%</td>
<td>Jensen Huang</td>
<td>-7.4</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>-16.67%</td>
<td>-9.25%</td>
<td>Tim Cook</td>
<td>-0.068</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>-10.86%</td>
<td>-2.36%</td>
<td>Bill Gates</td>
<td>-0.774</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-18.99%</td>
<td>-8.98%</td>
<td>Jeff Bezos</td>
<td>-16</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</td>
<td>-19.93%</td>
<td>-3.92%</td>
<td>Sundar Pichai</td>
<td>-0.018</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>-11.28%</td>
<td>-8.96%</td>
<td>Mark Zuckerberg</td>
<td>-17.9</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>-5.47%</td>
<td>-29.53%</td>
<td>Elon Musk</td>
<td>-8.7</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Forbes</figcaption></figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/04/44643368/donald-trump-says-market-is-going-to-boom-claiming-6-7-trillion-worth-of-inflows-will-come">Donald Trump Says &#8216;Market Is Going To Boom,&#8217; Claiming &#8216;$6-7 Trillion&#8217; Worth Of Inflows Will Come After The Worst Selloff Since 2020</a>
Why It Matters: The Dow Jones endured its fifth-worst day in history, shedding 1,679 points. It was Dow and S&amp;P 500&#8217;s worst trading day since June 2020. Meanwhile, the Nasdaq had its most significant single-day decline since March 2020.
Citing the necessity to rectify the United States' trade deficit, Trump utilized a 1977 statute to officially declare a trade emergency, subsequently introducing new tariffs on Wednesday.
He imposed a blanket 10% tariff on all trading partners and levied more duties on the countries he described as "bad actors".
It is worth noting that China, Vietnam, Cambodia, and Sri Lanka are subject to the most severe tariffs, whereas Canada and Mexico were exempted from &#8220;Liberation Day&#8221; tariffs.
Benchmark indices are in the correction zone. The S&amp;P 500 fell 12.22% from its Feb. 19th peak, the Nasdaq 100 dropped 16.65% from its 52-week high, approaching the bear market territory, and the Dow was down 10.05% as of Thursday.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Friday. The SPY was down 2.30% to $525.78, while the QQQ declined 2.52% to $439.32, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44642131/volatility-gauge-vix-surges-to-an-8-month-high-more-fear-more-opportunity-says-analyst" target="_blank" rel="noreferrer noopener">Volatility Gauge Vix Surges To An 8-Month High: ‘More Fear Equals More Opportunity,' Says Analyst</a></li>
</ul>
Image via Shutterstock

Equities

Markets

Tech

General

AAPL

AMZN

GOOG

GOOGL

MSFT

NVDA

TSLA

Elon Musk, Mark Zuckerberg And Jensen Huang See $34 Billion Wiped Out In A Single Day: Here's How Much Other 'Magnificent 7' Billionaires Lost After Trump's Liberation Day

IREN

IREN March 2025 Bitcoin Mined 533 BTC, Up From 459 BTC In Feb; Revenue $45.3M, Up From $43.9M In Feb

HC Wainwright &amp; Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and lowers the price target from $14 to $12.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $12

NTRB

Nutriband Inc. Signs Associate Partnership Deal With Charlotte FC To Boost Brand Visibility, Promote AI Tape

Rosenblatt analyst Mike Genovese upgrades Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from Neutral to Buy and lowers the price target from $115 to $85.

Upgrades

COHR

Rosenblatt Upgrades Coherent to Buy, Lowers Price Target to $85

AerCap Closes Q1 2025 With 112 Lease Deals, $1.5B Financing, And $558M Share Buyback

HC Wainwright &amp; Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and maintains $15 price target.

KALA

HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

Macro Economic Events

Economics

China Earlier Announced 34% Tariff On All U.S. Imports Starting April 10 In Response To U.S.Tariffs Imposed By President Trump

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and maintains $13 price target.

Telsey Advisory Group Maintains Market Perform on Guess, Maintains $13 Price Target

MSSA

Metal Sky Star To Be Delisted From Nasdaq After SPAC Deadline Miss, Will Move To OTC Market

HC Wainwright &amp; Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy and maintains $4 price target.

VANI

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

UTHR

United Therapeutics Corporation Says It Will Feature Clinical Data Across Its Commercial And Development Portfolio At International Society For Heart And Lung Transplantation 45th Annual Meeting And Scientific Sessions

<ul>
<li>Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation&nbsp;</li>
<li>Presentation featuring network meta-analysis of SYMBRAVO versus oral CGRPs</li>
</ul>

Biotech

Health Care

AXSM

Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting

NYAX

Nayax Plans To Maintain Current Hardware Pricing For US Customers, Despite New Tariffs Imposed On Imports To US

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and maintains $30 price target.

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Maintains $30 Price Target

<ul>
<li>Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year.</li>
<li>Approval brings AstraZeneca and Daiichi Sankyo's Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease.</li>
</ul>

Large Cap

The European Commission Approves AstraZeneca And Daiichi Sankyo's Enhertu (Trastuzumab Deruxtecan) As Monotherapy For Adult Patients With Unresectable Or Metastatic Hormone Receptor-positive, HER2-low Or HER2-ultralow Breast Cancer Who Have Received At Least One Endocrine Therapy In The Metastatic Setting And Who Are Not Considered Suitable For Endocrine Therapy As The Next Line Of Treatment

Press Releases

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Earnings

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Comments

Aquestive Therapeutics

Aquestive Therapeutics (AQST) Options

Aquestive Therapeutics (NASDAQ:AQST) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL